sarepta gene therapy - Search News

Order byBest matchMost fresh

News

Sarepta Will Resume Gene Therapy Shipments

· 1h · on MSN

FDA’s Vinay Prasad Exits After Sarepta Gene Therapy Controversy

Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his handling of Sarepta Therapeutics Inc.’s gene therapy.

Continue reading

· 10h · on MSN

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

· 1d · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

7don MSN

In a reversal, Sarepta says it will pause shipments of gene therapy linked to deaths

By Zachary Stieber Contributing Writer In a reversal, the drugmaker Sarepta Therapeutics said July 21 it is stopping all ...

9h

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

Sarepta stock sees upgrades and price hikes as analysts reassess Elevidys prospects following a favorable FDA development.

14h

Sarepta: SRPT Stock To $40?

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

4don MSN

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results